BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 30189247)

  • 1. PRMT5 inhibition promotes osteogenic differentiation of mesenchymal stromal cells and represses basal interferon stimulated gene expression.
    Kota SK; Roening C; Patel N; Kota SB; Baron R
    Bone; 2018 Dec; 117():37-46. PubMed ID: 30189247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
    Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y
    Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OGG1 regulates the level of symmetric dimethylation of histone H4 arginine-3 by interacting with PRMT5.
    Zhou X; Wang W; Du C; Yan F; Yang S; He K; Wang H; Zhao A
    Mol Cell Probes; 2018 Apr; 38():19-24. PubMed ID: 29409673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEP50/PRMT5 Reduces Gene Expression by Histone Arginine Methylation and this Is Reversed by PKCδ/p38δ Signaling.
    Saha K; Adhikary G; Eckert RL
    J Invest Dermatol; 2016 Jan; 136(1):214-224. PubMed ID: 26763441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone H4R3 symmetric di-methylation by Prmt5 protects against cardiac hypertrophy via regulation of Filip1L/β-catenin.
    Cai S; Wang P; Xie T; Li Z; Li J; Lan R; Ding Y; Lu J; Ye J; Wang J; Li Z; Liu P
    Pharmacol Res; 2020 Nov; 161():105104. PubMed ID: 32739429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of PRMT5 suppresses osteoclast differentiation and partially protects against ovariectomy-induced bone loss through downregulation of CXCL10 and RSAD2.
    Dong Y; Song C; Wang Y; Lei Z; Xu F; Guan H; Chen A; Li F
    Cell Signal; 2017 Jun; 34():55-65. PubMed ID: 28302565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of protein arginine methyltransferase 5 enhances hepatic mitochondrial biogenesis.
    Huang L; Liu J; Zhang XO; Sibley K; Najjar SM; Lee MM; Wu Q
    J Biol Chem; 2018 Jul; 293(28):10884-10894. PubMed ID: 29773653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRMT5-mediated histone arginine methylation antagonizes transcriptional repression by polycomb complex PRC2.
    Liu F; Xu Y; Lu X; Hamard PJ; Karl DL; Man N; Mookhtiar AK; Martinez C; Lossos IS; Sun J; Nimer SD
    Nucleic Acids Res; 2020 Apr; 48(6):2956-2968. PubMed ID: 32025719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetrical methyltransferase PRMT3 regulates human mesenchymal stem cell osteogenesis via miR-3648.
    Min Z; Xiaomeng L; Zheng L; Yangge D; Xuejiao L; Longwei L; Xiao Z; Yunsong L; Ping Z; Yongsheng Z
    Cell Death Dis; 2019 Aug; 10(8):581. PubMed ID: 31378783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomics profiling of arginine methylation defines PRMT5 substrate specificity.
    Musiani D; Bok J; Massignani E; Wu L; Tabaglio T; Ippolito MR; Cuomo A; Ozbek U; Zorgati H; Ghoshdastider U; Robinson RC; Guccione E; Bonaldi T
    Sci Signal; 2019 Apr; 12(575):. PubMed ID: 30940768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations.
    Ji S; Ma S; Wang WJ; Huang SZ; Wang TQ; Xiang R; Hu YG; Chen Q; Li LL; Yang SY
    Chem Biol Drug Des; 2017 Apr; 89(4):585-598. PubMed ID: 27714957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5.
    Zhang B; Zhang S; Zhu L; Chen X; Zhao Y; Chao L; Zhou J; Wang X; Zhang X; Ma N
    Toxicol Appl Pharmacol; 2017 Dec; 336():1-7. PubMed ID: 28987382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.
    Chen H; Lorton B; Gupta V; Shechter D
    Oncogene; 2017 Jan; 36(3):373-386. PubMed ID: 27270440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of substrate modifications on the arginine dimethylation activities of PRMT1 and PRMT5.
    Fulton MD; Dang T; Brown T; Zheng YG
    Epigenetics; 2022 Jan; 17(1):1-18. PubMed ID: 33380261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells.
    Wang L; Pal S; Sif S
    Mol Cell Biol; 2008 Oct; 28(20):6262-77. PubMed ID: 18694959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CARM1-mediated methylation of protein arginine methyltransferase 5 represses human γ-globin gene expression in erythroleukemia cells.
    Nie M; Wang Y; Guo C; Li X; Wang Y; Deng Y; Yao B; Gui T; Ma C; Liu M; Wang P; Wang R; Tan R; Fang M; Chen B; He Y; Huang DCS; Ju J; Zhao Q
    J Biol Chem; 2018 Nov; 293(45):17454-17463. PubMed ID: 30257864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein arginine methyltransferases PRMT1, PRMT4/CARM1 and PRMT5 have distinct functions in control of osteoblast differentiation.
    Dashti P; Lewallen EA; Gordon JAR; Montecino MA; van Leeuwen JPTM; Stein GS; van der Eerden BCJ; Davie JR; van Wijnen AJ
    Bone Rep; 2023 Dec; 19():101704. PubMed ID: 37593409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OXR1A, a Coactivator of PRMT5 Regulating Histone Arginine Methylation.
    Yang M; Lin X; Segers F; Suganthan R; Hildrestrand GA; Rinholm JE; Aas PA; Sousa MML; Holm S; Bolstad N; Warren D; Berge RK; Johansen RF; Yndestad A; Kristiansen E; Klungland A; Luna L; Eide L; Halvorsen B; Aukrust P; Bjørås M
    Cell Rep; 2020 Mar; 30(12):4165-4178.e7. PubMed ID: 32209476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autocrine fibroblast growth factor 18 mediates dexamethasone-induced osteogenic differentiation of murine mesenchymal stem cells.
    Hamidouche Z; Fromigué O; Nuber U; Vaudin P; Pages JC; Ebert R; Jakob F; Miraoui H; Marie PJ
    J Cell Physiol; 2010 Aug; 224(2):509-15. PubMed ID: 20432451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
    Sloan SL; Renaldo KA; Long M; Chung JH; Courtney LE; Shilo K; Youssef Y; Schlotter S; Brown F; Klamer BG; Zhang X; Yilmaz AS; Ozer HG; Valli VE; Vaddi K; Scherle P; Alinari L; Kisseberth WC; Baiocchi RA
    PLoS One; 2021; 16(5):e0250839. PubMed ID: 33989303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.